Next Generation Sequencing of MCF-7 and MDA-MB-435 cells
Ontology highlight
ABSTRACT: Human breast cancer cells MDA-MB-435 had higher metastatic potential and other aggressive characteristics than MCF-7 cells. Next-generation RNA sequencing (RNA-Seq) was used to clear this concern through comparison the transcriptomic expression profiles of these two cells. Total RNA were extracted from MCF-7 and MDA-MB-435S cells, and the polyA+ mRNA was sequenced using Illumina Genome Analyzer IIx. The reads were mapped to RefSeq RNA reference sequences.
Project description:Human breast cancer cells MDA-MB-435 had higher metastatic potential and other aggressive characteristics than MCF-7 cells. Next-generation RNA sequencing (RNA-Seq) was used to clear this concern through comparison the transcriptomic expression profiles of these two cells.
Project description:Transcriptional profiling of breast cancer cells comparing pre-control transfected cells with cells transfected with pre-miR-125b. We searched for miR-125b targets by systematic screening of mRNA profiling of pre-miR-125b transfected MCF-7 cells and MDA-MB-435 cells.
Project description:Transcriptional profiling of breast cancer cells comparing pre-control transfected cells with cells transfected with pre-miR-125b. We searched for miR-125b targets by systematic screening of mRNA profiling of pre-miR-125b transfected MCF-7 cells and MDA-MB-435 cells. Two-condition experiment, pre-miR-125b Transfected vs. pre-control Transfected MCF-7 cells. One replicate per array.
Project description:MDA-MB-435 breast cancer cells were treated with 2ME2 (2 µM) or vehicle alone. RNA was extracted and genomic profiling was performed using 22k Agilent microarrays. Keywords: Treatment-response
Project description:MDA-MB-435 breast cancer cells were treated with 2ME2 (2 µM) or vehicle alone. RNA was extracted and genomic profiling was performed using 22k Agilent microarrays. Experiment Overall Design: MDA-MB-435 breast cancer cells were treated with 2ME2 (2 µM) or vehicle alone. RNA was extracted and genomic profiling was performed using 22k Agilent microarrays.
Project description:In an effort to identify novel signaling molecules modulated by α-TEA, microarray analyses were performed. DNA array data obtained from human MDA-MB-435 breast cancer cells treated with 40 µM α-TEA for 12 h revealed over 400 genes that were consistently either up- or down-regulated. Thirty-four genes were selected based on their possible involvement in the known biological activities of α-TEA, and three: phorbol-12-myristate 13-acetate-induced protein (PMAPI) which codes for the protein NOXA, ABL2 which codes for the protein referred to as ARG (Abelson-related gene) and THBS1 which codes for thrombospondin 1, TSP-1 were chosen for further study. Keywords: Anti-cancer drug (aTEA at 40 uM 12 hour) treatment for MDA-MB-435 cells
Project description:In order to identify novel molecular targets associated with TNBC progression, we initially performed transcriptome analysis using RNA sequencing in breast cancer cell lines, classified as either the luminal subtype (MCF-7, T47D, ZR-75B) or basal-like subtype (MDA-MB-231, MDA-MB-435, Hs578T).
Project description:The objective of this study was to determine the gene expression changes mediated by the alpha6beta4 integrin using MDA-MB-435 breast carcinoma cell line under normal culturing conditions (10% FCS in DMEM). Experiment Overall Design: Comparison of clones of MDA-MB-435 cells transfected with the integrin beta4 subunit (which results in cell surface expression of the integrin apha6beta4 integrin; clones 3A7 and 5B3) to those transfected with vector (mock; 6D2 and 6D7) only.
Project description:This experiment performed RNA-seq of transcriptome and translatome (translating mRNA) of Caco-2 cells We extracted transcriptome and translatome from Caco-2 cells and deep sequenced them